WO2011105403A1 - Composition présentant un effet de soulagement des escarres - Google Patents

Composition présentant un effet de soulagement des escarres Download PDF

Info

Publication number
WO2011105403A1
WO2011105403A1 PCT/JP2011/053920 JP2011053920W WO2011105403A1 WO 2011105403 A1 WO2011105403 A1 WO 2011105403A1 JP 2011053920 W JP2011053920 W JP 2011053920W WO 2011105403 A1 WO2011105403 A1 WO 2011105403A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
pressure ulcer
lactic acid
composition according
present
Prior art date
Application number
PCT/JP2011/053920
Other languages
English (en)
Japanese (ja)
Inventor
卓巳 渡邉
隆充 塚原
薫 山田
Original Assignee
コンビ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンビ株式会社 filed Critical コンビ株式会社
Publication of WO2011105403A1 publication Critical patent/WO2011105403A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention relates to a composition having a pressure ulcer improving action. More specifically, the present invention relates to a composition having a pressure ulcer improving action containing lactic acid bacteria as an active ingredient, and its use as a medicine, reagent, and food and drink.
  • a pressure ulcer is a state in which blood flow to the skin, subcutaneous adipose tissue, and muscle is interrupted by continuous compression, and these tissues are killed.
  • local therapies including nursing, prevention, nutrition management, and skin care for the purpose of dispersion of body pressure are performed in order to secure local blood flow.
  • local treatment of pressure ulcers it is necessary to correctly determine the state of pressure ulcers, select treatments suitable for the state, external medicine, and wound dressing, and apply them to the patient.
  • the conventional local treatment of pressure ulcers since highly specialized knowledge is required, the development of a simpler new treatment method is required.
  • enterobacteria such as lactic acid bacteria
  • attempts have been made to verify the effect of preventing diseases and improving the symptoms of diseases, and can be easily consumed and used as highly safe medicines and foods and drinks. Yes.
  • EC-12 Enterococcus faecalis EC-12 strain
  • EC-12 is a lactic acid bacterium isolated from the human intestinal tract
  • the applicant of the present application has an effect of suppressing the contraction of villi.
  • Patent Document 1 Non-Patent Document 1
  • Patent Document 2 Non-Patent Documents 2 to 4
  • Listeria Protective effect against bacterial infection Non-patent document 5
  • Non-patent document 3 Listeria Protective effect against drug-resistant bacteria
  • Patent document 6 activation effect of innate and acquired immunity
  • Patent Document 4 Type I allergic reaction (asthma, hay fever, atopic dermatitis) alleviating effect
  • Patent Document 5 Non-Patent Document 7
  • Patent Document 6 rheumatoid arthritis improving effect
  • Patent Document 9 have reported such as anti-tumor effects (Non-Patent Document 8), and burns healing promoting effect
  • Non-Patent Document 9 Non-Patent Document 9
  • JP 2008-255080 A JP 2004-51530 A JP 2006-89421 JP 2006-28050 A JP 2007-91694 A JP 2007-254333 A JP 2007-290992 A
  • the present invention has been made in view of such circumstances, and an object of the present invention is a composition having a pressure ulcer improving action, which can be easily administered or ingested, and has a high safety. To provide things.
  • the present inventors examined the effect of lactic acid bacteria in a pressure ulcer model mouse. Specifically, this model mouse was ingested with Enterococcus faecalis (EC-12 strain) as an example of lactic acid bacteria, and its pressure ulcer improving action was evaluated. As a result, in this model mouse, the pressure ulcer area decreased from the early stage after pressure ulcer formation, and high expression of various inflammatory cytokines and growth factors was observed in the early stage after pressure ulcer formation. Turned out to be promoted. Furthermore, it was found that the expression of inflammatory cytokines and growth factors decreased later in the post- pressure ulcer formation, and they were heading toward a normal state faster than the control.
  • Enterococcus faecalis (EC-12 strain) showed its improving action from an early stage after pressure ulcer formation. Furthermore, comparing this with the negative control group and the group that received Enterococcus faecalis (EC-12 strain) on the same day, this effect was especially effective when Enterococcus faecalis (EC-12 strain) was administered prophylactically before the formation of pressure ulcers. It was also found that this was remarkable.
  • Enterococcus faecalis (EC-12 strain) is extremely useful as a medicine or food and drink for the prevention of pressure ulcer and healing at an early stage, thereby completing the present invention. It came to.
  • the present invention provides the following inventions.
  • a composition used for improving pressure ulcer comprising lactic acid bacteria as an active ingredient.
  • the pressure ulcer in the living body can be improved by administering the composition of the present invention as a pharmaceutical or ingesting as a food or drink.
  • the composition of the present invention can obtain a prominent effect by prophylactic administration before pressure ulcer formation.
  • the composition of the present invention is useful in the prevention of pressure ulcer and healing at an early stage of pressure ulcer.
  • the active ingredient of the composition of this invention is a lactic acid bacterium, and its safety is high. For this reason, when used as a medicine, it can be administered orally, and unlike conventional local treatments for pressure ulcers, it is simple and has less burden on pressure ulcer patients.
  • the composition of the present invention can be easily taken by a healthy person on a daily basis as a food or drink such as a health food to prevent pressure ulcers.
  • the present invention provides a composition for improving pressure ulcer comprising lactic acid bacteria as an active ingredient.
  • “decubitus” means a state in which blood flow to the skin, subcutaneous adipose tissue, and muscle is interrupted due to continuous compression, and these tissues are killed.
  • “decubitus ameliorating action” includes that pressure ulcers are less likely to occur by administration or ingestion of lactic acid bacteria, that the resulting pressure ulcers become mild, that pressure ulcer deterioration is suppressed, and that pressure ulcer healing is accelerated. I mean. Moreover, in the process until the formed pressure ulcer is healed, it is meant not only to improve the whole but also to improve a specific stage. The action of improving pressure ulcer can be evaluated, for example, by measuring the pressure ulcer area or measuring the expression of inflammatory cytokines and growth factors, as shown in this Example.
  • Examples of lactic acid bacteria belonging to the genus Enterococcus include Enterococcus faecalis and Enterococcus faecium.
  • Examples of bacteria belonging to the genus Bifidobacterium include, for example, Bifidobacterium longum, Bifidobacterium previ Bifidobacterium bifidum, and bacteria belonging to the genus Lactobacillus include Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivaius, and bacteria belonging to the genus Streptococcus include, for example, Streptococcus thermophilus Examples of bacteria belonging to the genus Lactococcus include Lactococcus cremolith and Lactococcus lactis.
  • the lactic acid bacteria used in the composition of the present invention are preferably those belonging to the genus Enterococcus, and particularly preferably Enterococcus faecalis.
  • Enterococcus faecalis EC-12 strain (EC-12) used in this example was incorporated on February 25, 2005 (original deposit date), National Institute of Advanced Industrial Science and Technology, Patent Biological Depositary Center ( ⁇ 305 -5466 Deposited at Tsukuba City, Ibaraki Prefecture, Japan, 1st Street, 1st Street, 1st Central, 1st 6th (Accession number is FERM BP-10284).
  • strains such as ATCC19433, ATCC14508, ATCC23655, IFO16803, and IFO16804 can be used in addition to the EC-12 strain.
  • lactic acid bacteria can be used as viable bacteria or dead cells.
  • Dead cells are preferred as an active ingredient of the composition of the present invention in that they are excellent in heat resistance, stable in quality, and tasteless and odorless.
  • heat-sterilized cells can be used as dead cells in the composition of the present invention. Heat-sterilized cells are collected from a culture obtained by culturing lactic acid bacteria according to a conventional method, for example, by filtration, centrifugation, or the like, and after washing with water, suspended in water or the like and 120 ° C.
  • composition of the present invention may be in the form of a pharmaceutical composition having a pressure ulcer improving action, a food or drink (including animal feed), or a reagent used for model animal experiments.
  • the composition of the present invention can be suitably used as a pharmaceutical composition that is administered prophylactically or as a food or drink that is taken prophylactically (daily), thereby preventing pressure ulcers or at an early stage. Can be cured.
  • the composition of the present invention contains inflammatory cytokines and growth factors (eg, IL-1 ⁇ gene, TNF- ⁇ gene, TGF- ⁇ gene, FGF-7 gene, FGF-10 gene) in the early stage after pressure ulcer formation.
  • inflammatory cytokines and growth factors eg, IL-1 ⁇ gene, TNF- ⁇ gene, TGF- ⁇ gene, FGF-7 gene, FGF-10 gene
  • composition for promoting expression suppression and inflammatory cytokines and growth factors (for example, IL-1 ⁇ gene, IL-8 gene, TNF- ⁇ gene, TGF- ⁇ gene, FGF- It can also be used as a composition for promoting suppression of expression of 10 genes).
  • inflammatory cytokines and growth factors for example, IL-1 ⁇ gene, IL-8 gene, TNF- ⁇ gene, TGF- ⁇ gene, FGF- It can also be used as a composition for promoting suppression of expression of 10 genes).
  • the composition in the present invention can be formulated by a known pharmaceutical method.
  • a known pharmaceutical method for example, capsule, tablet, pill, liquid, powder, granule, fine granule, film coating, pellet, troche, sublingual, chewing agent, buccal, paste, syrup, suspension, To be used orally or parenterally as elixirs, emulsions, coatings, ointments, plasters, cataplasms, transdermal preparations, lotions, inhalants, aerosols, injections, suppositories, etc. Can do.
  • the present invention is a composition comprising a lactic acid bacterium which is an enteric bacterium as an active ingredient, and can be easily administered or ingested orally. That is, the preferred method of administration or ingestion of the composition of the present invention is oral administration or ingestion.
  • carriers that are acceptable pharmacologically or as foods and beverages, specifically, sterile water and physiological saline, vegetable oils, solvents, bases, emulsifiers, suspensions, surfactants, stabilizers, Flavoring agent, fragrance, excipient, vehicle, preservative, binder, diluent, tonicity agent, soothing agent, extender, disintegrant, buffering agent, coating agent, lubricant, colorant, sweetness Can be suitably combined with an agent, a thickening agent, a flavoring agent, a solubilizing agent or other additives.
  • composition of the present invention when used as a pharmaceutical composition, it may be used in combination with a known pharmaceutical composition used for the prevention or treatment of pressure ulcers.
  • the food or drink can be, for example, a health food, a functional food, a food for specified health use, a nutritional supplement, a food for a sick person, or an animal feed.
  • the food / beverage products of this invention can be ingested as a composition as described above, and can also be ingested as various food / beverage products.
  • food and drink include juices, soft drinks, tea drinks, drinks, jelly-like drinks, functional drinks and other drinks; beer and other alcoholic drinks; rice, noodles, breads and pasta Carbohydrate-containing foods; paste products such as fish ham, sausage and fish paste products; retort products such as curry, sauce, and Chinese soup; soups; dairy products such as milk, milk drinks, ice cream, cheese, and yogurt; Fermented products such as lactic acid bacteria, fermented beverages and pickles; Bean products; Western confectionery such as biscuits and cookies; Japanese confectionery such as buns and sheep candy; Kinds: Instant foods such as instant soup and instant miso soup, foods compatible with microwave ovens, and the like.
  • health foods and drinks prepared in the form of powder, granules, tablets, capsules, liquid, paste or jelly are also included.
  • composition of the present invention can be used for animals including humans, but is not particularly limited as animals other than humans, and may be used for various domestic animals, poultry, pets, laboratory animals, and the like. it can. Specific examples include but are not limited to pigs, cows, horses, sheep, goats, chickens, ducks, ostriches, ducks, dogs, cats, rabbits, hamsters, mice, rats, monkeys, and the like.
  • the production of food and drink in the present invention can be performed by a production technique known in the technical field.
  • one or more components for example, nutrients
  • the dose or ingestion is appropriately determined according to the age, weight, pressure ulcer symptoms, health condition, type of composition (pharmaceuticals, food and drink, etc.), etc. Selected.
  • the dose or intake of lactic acid bacteria per dose is generally 0.01 mg / kg body weight to 100 mg / kg body weight, preferably 1 mg / kg body weight to 10 mg / kg body weight.
  • the present invention also provides a method for improving pressure ulcers in a subject, characterized by administering or ingesting lactic acid bacteria to the subject.
  • the product of the composition of the present invention may be labeled with an indication that it is used to improve pressure ulcers.
  • labeled product or instructions means that the product body, container, packaging, etc. are marked, or instructions, package inserts, promotional materials, or other printed materials that disclose product information. It means that the display is attached to.
  • the indication that it is used to improve pressure ulcers can include information on the mechanism by which the pressure ulcer is improved by administering or ingesting lactic acid bacteria.
  • Mechanisms include, for example, inflammatory cytokines and growth factors associated with pressure ulcers (eg, IL-1 ⁇ gene, IL-8 gene, TNF- ⁇ gene, TGF- ⁇ gene, FGF-7 gene, FGF-10 gene) Information on its action and expression.
  • inflammatory cytokines and growth factors associated with pressure ulcers eg, IL-1 ⁇ gene, IL-8 gene, TNF- ⁇ gene, TGF- ⁇ gene, FGF-7 gene, FGF-10 gene
  • Example 1 Examination of the pressure ulcer improvement effect of EC-12 in a mouse model BALB / c 10-week-old male mice were used as test animals. “Saline administration group (control group)”, “Prophylactic EC-12 administration group” and “Same day EC-12 administration group” were set as test groups, and 15 mice (45 in total) were assigned to each group. Using.
  • mice are suspended daily so that EC-12 is suspended in physiological saline and EC-12 is 10 mg / kg (body weight).
  • Sterile saline was orally administered to the “saline administration group”.
  • Administration of EC-12 to the “preventive EC-12 administration group” and the administration of physiological saline to the “saline administration group” started 7 days before the start of pressure ulcer and once a day until necropsy in the morning I went at 9 o'clock.
  • EC-12 administration to the “same day EC-12 administration group” started from the day of pressure ulcer preparation and was performed once a day at 9:00 am until autopsy.
  • the condition of the wound part was observed daily and photographed, and the area of the wound part was measured by image analysis of the photograph.
  • 5 autopsies were performed in each group. Somnopentyl (Schering plow) was intraperitoneally administered, and after deep anesthesia, it was sacrificed by exsanguination.
  • the wound area reduction rate was calculated as a value when the maximum pressure ulcer area of the “preventive EC-12 administration group” was 100.
  • the wound area reduction rate was lower in the “prophylactic EC-12 administration group” than the “same day EC-12 administration group” and the “saline administration group” from the fourth day after pressure ulcer formation. Values are shown (FIG. 1).
  • the present inventors further confirmed the mRNA expression of cytokines and growth factors for the wound sample.
  • IL-8 is a leukocyte chemotactic factor that is produced from various cells such as leukocytes, fibroblasts and endothelial cells by stimulation of inflammatory cytokines such as IL-1 and TNF. factor).
  • IL-1 ⁇ has various physiological activities in various immunocompetent cells, but its most important function is to induce IL-2 production of helper T cells and to differentiate T cells via IL-2.
  • -It is known to promote proliferation.
  • TNF- ⁇ is considered to be one of mediators in inflammatory reactions because it induces fever and various inflammatory reactions through the production of IL-1, PGE2, collagenase and the like.
  • TGF- ⁇ is known to promote the migration of macrophages to the damaged site when the tissue is damaged. Since macrophages themselves also secrete TGF- ⁇ , this secretion increases fibroblasts and synergistically accelerates the wound healing process.
  • FGF-7 is a multifunctional signal molecule that exhibits activities such as proliferation and differentiation to various cells as well as fibroblasts, and is also called KGF (keratinocyte growth factor).
  • FGF-10 is a family of fibroblast growth factors and is located in the FGF-7 subfamily.
  • IL-1 ⁇ , IL-8, and TNF- ⁇ as cytokines and the above-described TGF- ⁇ , FGF-7, and FGF-10 as growth factors were examined. .
  • cDNA was synthesized by reverse transcription, and the cDNA was used as a template and real-time PCR (Rotor-Gene 6200 (Qiagen)) using the primers shown in Table 1 was done.
  • RNA extraction QuickGene 810 system and QuickGene RNA tissue kit SII (Fujifilm) were used, and for reverse transcription, PrimeScript RT RT reagent kit (Perfect Real Time; Takara Bio) was used. The work was performed in accordance with the instruction manual. The measured value was corrected with GAPDH.
  • the process from pressure ulcer development to healing is generally classified into four stages: (1) bleeding coagulation phase, (2) inflammation phase, (3) proliferative phase, and (4) mature phase.
  • a significant decrease in the pressure ulcer area was observed on the fourth day of the pressure ulcer compared with the “same day EC-12 administration group” and the “saline administration group”.
  • high expression of inflammatory cytokines and growth factors was observed on the 3rd day of the pressure ulcer development, and thereafter, their expression was dramatically decreased on the 6th day of the pressure ulcer development. From these facts, it was shown that administration of EC-12 before the pressure ulcer formation was effective in healing pressure ulcers at the early stage of pressure ulcer development. These facts also suggested that EC-12 is useful for preventing pressure ulcers.
  • pressure ulcers in a living body can be improved by administering the composition of the present invention as a pharmaceutical or ingesting as a food or drink.
  • Lactic acid bacteria which are active ingredients of the composition of the present invention, are enteric bacteria and can be administered or taken orally. Since the composition of the present invention is highly safe and can be easily administered or ingested, it is expected to be used as a new medicine or health food having an action to improve pressure ulcers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

Lorsqu'elle est administrée à des souris modèles d'escarres pour étudier l'effet de soulagement des escarres, une souche d'Enterococcus faecalis (souche EC-12), qui est un exemple de bactérie à acide lactique, présente un effet significatif de soulagement des escarres dès les premiers stades après la formation des escarres chez les souris. Ainsi, il est clarifié que la souche d'Enterococcus faecalis (souche EC-12) peut être employée de façon très avantageuse dans les médicaments, les aliments et les boissons pour prévenir les escarres ou les guérir dès les premiers stades.
PCT/JP2011/053920 2010-02-26 2011-02-23 Composition présentant un effet de soulagement des escarres WO2011105403A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-042303 2010-02-26
JP2010042303A JP5612870B2 (ja) 2010-02-26 2010-02-26 褥瘡改善作用を有する組成物

Publications (1)

Publication Number Publication Date
WO2011105403A1 true WO2011105403A1 (fr) 2011-09-01

Family

ID=44506808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/053920 WO2011105403A1 (fr) 2010-02-26 2011-02-23 Composition présentant un effet de soulagement des escarres

Country Status (3)

Country Link
JP (1) JP5612870B2 (fr)
TW (1) TWI477279B (fr)
WO (1) WO2011105403A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6185041B2 (ja) * 2015-12-04 2017-08-23 一丸ファルコス株式会社 表皮ブドウ球菌由来のグリセロール産生促進剤、皮膚表皮角化細胞由来の抗菌ペプチド産生促進剤、およびそれらの皮膚保護用外用剤への利用
JP2017128522A (ja) * 2016-01-19 2017-07-27 公立大学法人岩手県立大学 創傷治癒促進組成物
JP2018172329A (ja) * 2017-03-31 2018-11-08 公立大学法人岩手県立大学 肉芽形成促進組成物
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280773A (zh) * 2000-08-09 2001-01-24 郭兴华 天然抗菌组合物及其应用
JP2003253262A (ja) * 2002-02-28 2003-09-10 Snow Brand Milk Prod Co Ltd 抗酸化剤
WO2005012503A1 (fr) * 2003-07-30 2005-02-10 Bhph Company Limited Nouveau lactobacille, preparation de lactobacilles activant un corps vivant et agent preventif ou therapeutique agissant contre une infection par un corps vivant
JP2006028050A (ja) * 2004-07-14 2006-02-02 Combi Corp 皮膚アレルギー抑制組成物
JP2007091694A (ja) * 2005-09-30 2007-04-12 Combi Corp スギ花粉又はハウスダスト特異的ＩｇＥ抗体産生抑制剤、及び該抗原特異的ＩｇＥ抗体産生抑制のために用いられる飲食品
JP2007126399A (ja) * 2005-11-04 2007-05-24 Suntory Ltd グルタチオン増加用組成物
JP2007254333A (ja) * 2006-03-22 2007-10-04 Kitasato Gakuen 炎症抑制作用のある菌体含有組成物
JP2007290992A (ja) * 2006-04-24 2007-11-08 Kitasato Gakuen ハンセン病発症予防作用のある菌体含有組成物
JP2010173991A (ja) * 2009-01-30 2010-08-12 Kouai Kagaku Co Ltd 皮膚外用剤

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280773A (zh) * 2000-08-09 2001-01-24 郭兴华 天然抗菌组合物及其应用
JP2003253262A (ja) * 2002-02-28 2003-09-10 Snow Brand Milk Prod Co Ltd 抗酸化剤
WO2005012503A1 (fr) * 2003-07-30 2005-02-10 Bhph Company Limited Nouveau lactobacille, preparation de lactobacilles activant un corps vivant et agent preventif ou therapeutique agissant contre une infection par un corps vivant
JP2006028050A (ja) * 2004-07-14 2006-02-02 Combi Corp 皮膚アレルギー抑制組成物
JP2007091694A (ja) * 2005-09-30 2007-04-12 Combi Corp スギ花粉又はハウスダスト特異的ＩｇＥ抗体産生抑制剤、及び該抗原特異的ＩｇＥ抗体産生抑制のために用いられる飲食品
JP2007126399A (ja) * 2005-11-04 2007-05-24 Suntory Ltd グルタチオン増加用組成物
JP2007254333A (ja) * 2006-03-22 2007-10-04 Kitasato Gakuen 炎症抑制作用のある菌体含有組成物
JP2007290992A (ja) * 2006-04-24 2007-11-08 Kitasato Gakuen ハンセン病発症予防作用のある菌体含有組成物
JP2010173991A (ja) * 2009-01-30 2010-08-12 Kouai Kagaku Co Ltd 皮膚外用剤

Also Published As

Publication number Publication date
TW201141495A (en) 2011-12-01
JP5612870B2 (ja) 2014-10-22
TWI477279B (zh) 2015-03-21
JP2011178683A (ja) 2011-09-15

Similar Documents

Publication Publication Date Title
JP5718917B2 (ja) 新規なラクトバチルス・プランタラム及びこれを含む組成物
US9750775B2 (en) Lactic acid bacterium-containing preparation
US11268064B2 (en) Lactobacillus rhamnosus RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases
TW200944215A (en) Lactobacillus isolates having anti-inflammatory activities and uses of the same
EP3033091A1 (fr) Méthode et compositions de traitement d'un cancer à l'aide d'une référence croisée de probiotiques à une application associée
KR20090122454A (ko) 내장지방 감소제
WO2006093022A1 (fr) Agent modulant la fonction immune
JP5925274B2 (ja) 子宮内膜症の予防及び／又は改善剤及びこれを含んでなる飲食品組成物
JP2022539139A (ja) 腸管免疫調節のための新規なプロバイオティック組成物
WO2020118576A1 (fr) Utilisation de lactobacillus plantarum twk10 dans la préparation d'une composition pour une résistance à une inflammation post-exercice ou pour réduire la graisse corporelle
JP5612870B2 (ja) 褥瘡改善作用を有する組成物
KR102224072B1 (ko) 면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도
JP2008063289A (ja) 血中アディポネクチン濃度増加促進及び／又は減少抑制剤
WO2020067422A1 (fr) Composition permettant d'activer des lymphocytes t
CN108495643A (zh) 新型发酵乳杆菌菌株的组合物和使用方法
JP4479162B2 (ja) 免疫機能調節剤および免疫機能調節食品
JP6016326B2 (ja) 乳酸菌のスクリーニング方法
KR102502978B1 (ko) 케피어 유래 유산균의 세포표면단백질을 함유하는 항염증 또는 면역증강용 조성물
KR102485269B1 (ko) 비피도박테리움 비피덤을 포함하는 면역력 증강 또는 개선용 조성물
TWI705817B (zh) 胚芽乳酸桿菌ｔｗｋ１０用於製備抗運動後發炎醫藥組合物之用途
US20220387524A1 (en) Novel kimchi-derived lactobacillus fermentum strain with excellent anti-inflammatory activity and composition including same for prevention and treatment of inflammatory diseases
CN114949202A (zh) 一种益生菌和蛋白质的组合物及其抗幽门螺旋杆菌的应用
TW202027621A (zh) 胚芽乳酸桿菌ｔｗｋ１０用於製備降體脂醫藥組合物之用途
CN111297912A (zh) 胚芽乳酸杆菌twk10制备抗运动后发炎或降体脂组合物的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11747363

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11747363

Country of ref document: EP

Kind code of ref document: A1